Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score
出版年份 2022 全文链接
标题
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score
作者
关键词
-
出版物
CNS DRUGS
Volume 36, Issue 2, Pages 191-202
出版商
Springer Science and Business Media LLC
发表日期
2022-02-11
DOI
10.1007/s40263-021-00893-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
- (2021) Messoud Ashina et al. EUROPEAN JOURNAL OF NEUROLOGY
- Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study
- (2021) Stewart J. Tepper et al. JOURNAL OF HEADACHE AND PAIN
- Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
- (2021) Fabrizio Vernieri et al. JOURNAL OF HEADACHE AND PAIN
- The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study
- (2021) Marta Torres-Ferrús et al. JOURNAL OF NEUROLOGY
- Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
- (2021) Andrew M. Blumenfeld et al. Pain and Therapy
- Refractory migraine profile in CGRP‐monoclonal antibodies scenario
- (2021) Marcello Silvestro et al. ACTA NEUROLOGICA SCANDINAVICA
- Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
- (2021) Piero Barbanti et al. HEADACHE
- Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache
- (2021) Umberto Pensato et al. NEUROLOGICAL SCIENCES
- Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?
- (2021) Theodoros Mavridis et al. Pharmaceuticals
- Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
- (2020) Stewart J Tepper et al. CEPHALALGIA
- Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
- (2020) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
- (2020) Bianca Raffaelli et al. Frontiers in Neurology
- Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
- (2020) Rami Burstein et al. HEADACHE
- Access to Migraine Treatments in Ontario, Canada: A Review of the Ontario Drug Benefit Program
- (2020) Susan Cape HEADACHE
- European headache federation consensus on the definition of resistant and refractory migraine
- (2020) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
- (2020) Antonio Russo et al. JOURNAL OF HEADACHE AND PAIN
- A prospective real-world analysis of erenumab in refractory chronic migraine
- (2020) Giorgio Lambru et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
- (2020) Armin Scheffler et al. JOURNAL OF HEADACHE AND PAIN
- Real-world effectiveness and tolerability of erenumab: A retrospective cohort study
- (2020) Saad Kanaan et al. CEPHALALGIA
- Erenumab in Chronic Migraine: An Australian Experience
- (2020) Shuli Cheng et al. HEADACHE
- Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine
- (2020) Jennifer Robblee et al. HEADACHE
- Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)
- (2020) Fabrizio Vernieri et al. NEUROLOGICAL SCIENCES
- One year experience with erenumab: real-life data in 30 consecutive patients
- (2020) Angelo Ranieri et al. NEUROLOGICAL SCIENCES
- Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center
- (2020) Eleonora Matteo et al. NEUROLOGICAL SCIENCES
- Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study
- (2020) Francesca Schiano di Cola et al. NEUROLOGICAL SCIENCES
- Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study
- (2020) Piero Barbanti et al. HEADACHE
- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
- (2019) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in chronic migraine with medication overuse
- (2019) Stewart J. Tepper et al. NEUROLOGY
- Blocking CGRP in migraine patients – a review of pros and cons
- (2017) Marie Deen et al. JOURNAL OF HEADACHE AND PAIN
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now